Arcus Biosciences Reports Q1 Loss, 39% Revenue Drop; Discontinues Key Clinical Trials & Faces Reduced Gilead Collaboration
RCUS has more than doubled off its 52-week low of $7.06.
Summary
Arcus Biosciences reported a 39.3% Q1 revenue decline and increased net loss, alongside the discontinuation of two key clinical trials and a reduced collaboration scope with Gilead, despite extending its cash runway.
Key Events · Earnings and Guidance · RCUS
-
Significant Revenue Decline
Total revenues for Q1 2026 decreased by 39.3% year-over-year to $17 million, primarily due to lower development services revenue from the Gilead Collaboration.
-
Increased Net Loss
The company reported a net loss of $128 million for Q1 2026, an increase from $112 million in Q1 2025.
-
Major Clinical Trial Discontinuations
The Phase 3 STAR-121 study for domvanalimab in NSCLC was discontinued due to futility, and enrollment in the Phase 1b/3 eVOLVE-RCC02 study for casdatifan in renal cell carcinoma was halted due to potential immune-mediated adverse events.
-
Reduced Gilead Collaboration Scope
Gilead decided not to make an option continuation payment, leading to the expiration of its option rights to several early-stage pipeline programs (CCR6, CD89, CD40L) by July 14, 2026. This follows Gilead's Q2 2025 termination of rights to the etrumadenant program.
Analysis · RCUS · Life Sciences
Arcus Biosciences' first-quarter report reveals significant setbacks, including a substantial 39.3% year-over-year revenue decline and an increased net loss. Critically, the company announced the discontinuation of its Phase 3 STAR-121 study due to futility and halted enrollment in the eVOLVE-RCC02 trial due to adverse events. These clinical failures are major negative developments for a clinical-stage biopharmaceutical company, impacting its pipeline and future revenue potential. Furthermore, Gilead's decision not to exercise options on several early-stage programs and its prior termination of rights to etrumadenant signal a reduction in the scope of their collaboration. While the company has extended its liquidity runway to the second half of 2028, this is set against a backdrop of significant operational challenges and pipeline contraction.
At the time of this filing, RCUS was trading at $25.40 on NYSE in the Life Sciences sector, with a market capitalization of approximately $3.3B. The 52-week trading range was $7.06 to $28.72. This filing was assessed with negative market sentiment and an importance score of 9 out of 10.